Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Pluri Inc
PLUR
Healthcare
Biotechnology
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and...
manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PLUR)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(76)
•••
lucaM1
X
Post by
lucaM1
on Jul 27, 2022 8:56am
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries o As of July
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Jul 25, 2022 7:00am
New Press Release - Pluri CEO Issues Shareholder Update
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jul 25, 2022 1:00am
New Press Release - Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
As ofJuly 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and...
read article.
(76)
•••
lucaM1
X
Post by
lucaM1
on Jul 19, 2022 9:51am
Pluristem trial shows accelerated muscle regeneration
Phase III study of allogeneic PLX-PAD cells confirms “regenerative medicine is effective in elderly”. https://longevity.technology/pluristem-trial-shows-accelerated-muscle-regeneration/
(76)
•••
lucaM1
X
Post by
lucaM1
on Jul 17, 2022 9:52am
HC Wainwright Reiterates On Pluristem After Encouraging Init
Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture
...more
(76)
•••
lucaM1
X
Post by
lucaM1
on Jul 13, 2022 8:35am
Pluristem's CEO on today's results
“While we were disappointed that this significant benefit did not translate to an SPPB score improvement, Pluristem will seek further regulatory advice to find a way to bridge the gap between
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Jul 13, 2022 6:00am
New Press Release - Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpAHAIFA, Israel, July 13, 2022 (GLOBE...
read article.
(76)
•••
lucaM1
X
Post by
lucaM1
on Jul 10, 2022 9:55am
A New Food Ecosystem Emerges in Israel
The story of of Pluristem got into cultured meat. https://www.ift.org/news-and-publications/food-technology-magazine/issues/2022/july/columns/startups-innovators-new-food-ecosystem-israel
(76)
•••
lucaM1
X
Post by
lucaM1
on Jul 06, 2022 4:06am
Effective Cell Therapy for Cocaine Addiction
Pluristem's Placenta-Derived Mesenchymal-like Adherent Stromal Cells as an Effective Cell Therapy for Cocaine Addiction in a Rat Model https://www.pluristem.com/wp-content/uploads/2022/07
...more
(76)
•••
lucaM1
X
Post by
lucaM1
on Jul 04, 2022 8:45am
PSTI reminder.
A friendly reminder: If the phase 3 results of the muscle regeneration trials will be positive, the next step would be FDA approval!
(76)
•••
lucaM1
X
Post by
lucaM1
on Jun 30, 2022 8:57am
$PSTI Q3 Wishlist
1. Results from the multinational Phase III study for muscle regeneration following hip fracture surgery 2. Cultured meat proof of concept.
(76)
•••
lucaM1
X
Post by
lucaM1
on Jun 13, 2022 8:43am
Cultured meat proof of concept
Cultured meat proof of concept is right around the corner as the company said it will be published in Q2 at their investor call earlier this year.
(76)
•••
lucaM1
X
Post by
lucaM1
on Jun 07, 2022 9:31am
New PSTI Company blog.
How can Pluristem’s technology help the environment? https://www.pluristem.com/pluristem-blog/how-can-pluristems-technology-help-the-environment/
(76)
•••
lucaM1
X
Post by
lucaM1
on May 25, 2022 10:22am
Bull run alert!
Bull run alert! Watch out, $PSTI is already up by 6% to start the day!
(76)
•••
lucaM1
X
Post by
lucaM1
on May 23, 2022 12:10pm
$PSTI vs S&P 500 YTD
$PSTI: -1% S&P 500: -17% $PSTI currently outperforming by 16%
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Silver is Considered a Safe Haven Asset But the White Metal Has Far More to it Than Meets the Eye
814 gpt Silver Over 1.0 M Within 6 Meters of 435 gpt and 174 gpt Over 22 M at Columba Silver Project
New Images for the Passive Seismic Survey Very Promising for the Topaz Helium Project in Minnesota